Koshinemall Bewertungen 22

Vom Unternehmen geschrieben

Koshine Hong Kong Limited is a wholly-owned subsidiary invested by Kintor Pharmaceutical Limited. Established in 2009, Kintor Pharmaceutical Limited is dedicated to the development and industrialization of potential "best-in-class" and "first-in-class" innovative drugs and high-end cosmetics, with the aiming of becoming a leading enterprise in the industry. After several years of development, the Company has established a diverse product pipeline focused on dermatology and oncology. Our range includes solutions for globally prevalent diseases and extends to high-end cosmetics, addressing the needs of both clinical dermatology and cosmetic consumers worldwide. Leveraging the same rigorous scientific research that has driven our pharmaceutical innovations, our cosmeceuticals are developed with the utmost efficacy and safety. Kintor Pharma's portfolio features cutting-edge small molecules and biologic drugs, with five products in clinical development and several in preclinical research. With over 100 patents granted worldwide, we are committed to advancing both therapeutic and cosmetic solutions. For more information about Kintor Pharmaceuticals’broader innovations and achievements, please visit website:https://www.kintor.com.cn/ . Koshine Hong Kong harnesses this rich scientific heritage to deliver advanced beauty solutions, addressing real consumer needs with proven efficacy. On 22 May 2020, Kintor Pharma was officially listed on the Hong Kong Stock Exchange with the stock code :9939.HK.Mehr ansehen